cancer therapeutics
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
Ilana Chefetz Confronts Ovarian Cancer
Ilana Chefetz Confronts Ovarian Cancer
Jim Daley | Apr 1, 2018
The University of Minnesota researcher is on the front lines in the fight against the disease.
Mutant RAS Proteins Team Up for Oncogenicity
Mutant RAS Proteins Team Up for Oncogenicity
Jim Daley | Apr 1, 2018
Mice with cancer whose KRAS proteins couldn’t link together had much better survival outcomes than those whose oncogenic mutant paired with wild-type KRAS.
Researchers Develop Sperm-Robot Hybrids to Deliver Drugs, Assist Fertilization
Researchers Develop Sperm-Robot Hybrids to Deliver Drugs, Assist Fertilization
Diana Kwon | Apr 1, 2018
The artificially motorized cells may one day help fight cancers in the female reproductive tract.
Researchers Getting Smarter About Pairing Cancer Treatments
Researchers Getting Smarter About Pairing Cancer Treatments
Anna Azvolinsky | Apr 1, 2018
Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.
DNA Robots Target Cancer
DNA Robots Target Cancer
Abby Olena | Feb 12, 2018
Researchers use DNA origami to generate tiny mechanical devices that deliver a drug that cuts off the blood supply to tumors in mice.
Cancers Relapse by Feeding Off Immune Signals
Cancers Relapse by Feeding Off Immune Signals
Shawna Williams | Oct 16, 2017
In mice, the tumor cells are able to thwart the immune response that would kill them—but immunotherapy prevented the return of melanoma.
FDA Approves Bladder Cancer Immunotherapy
FDA Approves Bladder Cancer Immunotherapy
Jef Akst | May 23, 2016
The US Food and Drug Administration greenlights Roche’s Tecentriq, which blocks a protein that obstructs the immune system’s ability to fight cancer.
FDA OKs Herpesvirus to Treat Cancer
FDA OKs Herpesvirus to Treat Cancer
Jef Akst | Oct 28, 2015
The US Food and Drug Administration’s approval of an engineered herpesvirus for the treatment of melanoma marks the first oncolytic virus to enter the market.
CAR-T Therapies Get $1 Billion Boost
CAR-T Therapies Get $1 Billion Boost
Bob Grant | Jul 1, 2015
The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.